Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

Tol, Jolien; Koopman, Miriam; Cats, Annemieke; J. Rodenburg, C.; Creemers, G.J.; Schrama, Jolanda; Erdkamp, Frans; H. Vos, Allert; J. van Groeningen, Cees; Sinnige, Harm; J. Richel, D.; E. Voest, Emile; R. Dijkstra, Jeroen; Elisa Vink-Börger, M.; Antonini, Ninja; Mol, Linda; Han van Krieken, J.; Dalesio, Otilia; J.A. Punt, Cornelis

doi:10.1056/nejmoa0808268

Public

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

Published in New England Journal of Medicine • Feb 4, 2009

Authors:

Jolien Tol

Miriam Koopman

Annemieke Cats

Abstract

BACKGROUND: Fluoropyrimidine-based chemotherapy plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab is standard first-line treatment for metastatic colorectal cancer. We studied the effect of adding the anti-epidermal growth factor receptor (EGFR) antibody cetuximab to a com...

Subject

Cetuximab

Medicine

Bevacizumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!